LONDON, March 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Hospira Inc. (NYSE: HSP), VIVUS Inc. (NASDAQ: VVUS), and Akorn Inc. (NASDAQ: AKRX). Free research report on Mylan can be accessed at http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL. The US markets declined on Wednesday, March 25, 2015, as the Dow Jones Industrial Average finished at 17,718.54, down 1.62% and the NASDAQ Composite closed at 4,876.52, down 2.37%. The S&P 500 finished the session 1.46% lower at 2,061.05. During the trading session, nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 840.82, down 1.84%, whereas the index has advanced 5.77% in the previous three months. Register for your complimentary reports at the links given below.

On Wednesday, Mylan N.V.'s stock lost 2.95%, to close the day at $61.23. The stock recorded a trading volume of 4.42 million shares, above its three months average volume of 3.69 million shares. The company's shares oscillated between $60.93 and $63.97 during the session. Over the last one month and over the previous three months, Mylan N.V.'s shares have advanced 8.37% and 7.48%, respectively. Further, the stock has gained 20.75% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Mylan N.V.'s 50-day moving average of $56.77 is above its 200-day moving average of $52.66. Additionally, the stock traded at a PE ratio of 20.43 and has a Relative Strength Index (RSI) of 62.51. Sign up and read the free notes on MYL at:

http://get.Investor-Edge.com/pdf/?c=Mylan&d=26-Mar-2015&s=MYL

On Wednesday, shares in Salix Pharmaceuticals Ltd recorded a trading volume of 1.15 million shares, lower than its three months average volume of 3.31 million shares. The stock ended the day at $172.55, which was 0.01% above its previous day's closing of $172.53, and registered an intraday range of $172.53 and $172.69. Salix Pharmaceuticals Ltd's shares have gained 10.14% in the last one month, 50.15% in the previous three months, and 68.01% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $147.82 and $135.08, respectively. Furthermore, shares of Salix Pharmaceuticals Ltd have an RSI of 83.40. The complimentary notes on SLXP can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Salix%20Pharma&d=26-Mar-2015&s=SLXP

Hospira Inc.'s stock edged 0.28% lower to end Wednesday's session at $87.75. The stock recorded a trading volume of 1.67 million shares, below its three months average volume of 3.00 million shares. The company's shares fluctuated between $87.75 and $88.05 during the session. Shares of the company traded at a PE ratio of 40.40. Hospira Inc.'s shares have rallied 111.60% in the past one year. Further, the stock has gained 0.30% over the last one month and 40.18% in the previous three months. The company's shares are trading above their 50-day and 200-day moving averages. Hospira Inc.'s 50-day moving average of $79.50 is above its 200-day moving average of $60.90. Additionally, the stock has an RSI of 83.31. Register for free on Investor-Edge and access the latest research on HSP at:

http://get.Investor-Edge.com/pdf/?c=Hospira&d=26-Mar-2015&s=HSP

On Wednesday, shares in VIVUS Inc. fluctuated between $2.61 and $2.78 before ending the session 5.43% lower at $2.61. The stock reported a trading volume of 2.25 million shares, lower than its three months average volume of 2.52 million shares. Although VIVUS Inc.'s stock has advanced 2.76% in the last one month, it has lost 12.12% in the previous three trading sessions and 12.85% in the past three months. The stock is trading below its 50-day and 200-day moving averages of $2.77 and $3.67, respectively. Moreover, shares of VIVUS Inc. have an RSI of 46.89. The complete research on VVUS is available for free at:

http://get.Investor-Edge.com/pdf/?c=VIVUS&d=26-Mar-2015&s=VVUS

Akorn Inc.'s stock finished Wednesday's session 5.19% lower at $45.66. A total of 1.80 million shares were traded, which was below its three months average volume of 2.03 million shares. The stock vacillated between $45.60 and $48.64 during the session. Over the last one month, the stock has fallen by 1.59%. However, over the previous three months and over the past one year, Akorn Inc.'s shares have surged 25.20% and 107.17%, respectively. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $46.09 is greater than its 200-day moving average of $38.83. Akorn Inc.'s stock traded at a PE ratio of 97.26 and has an RSI of 52.26. Free in depth research on AKRX is available at:

http://get.Investor-Edge.com/pdf/?c=Akorn&d=26-Mar-2015&s=AKRX

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge